Aktis Oncology (US.AKTS)
资本配置审计 · 期间： 2022 – 2026
核心指标
US.AKTS · 同比： 2026 Q1 vs 2025 Q1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 107.6% | → |
| ROE | -3.6% | → |
| Cash Conversion | - | → |
| D/E Ratio | 0.02 | → |
| Gross Margin | 0.0% | ↓ |
US.AKTS (Aktis Oncology) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 107.6% → ROE -3.6% → Cash Conversion - → D/E Ratio 0.02 → Gross Margin 0.0% ↓
核心指标
US.AKTS (Aktis Oncology) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 107.6% →ROE -3.6% →Cash Conversion - →D/E Ratio 0.02 →Gross Margin 0.0% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies